Cipla secures exclusive marketing and distribution deal for Pfizer brands

Cipla Limited has signed an exclusive supply and marketing agreement with Pfizer Products India Private Limited and Pfizer Limited for a period of five years within India. This agreement grants Cipla the sole right to market, distribute, and sell four Pfizer brands: Corex (Dx and LS cough syrup), Dolonex (non-steroidal anti-inflammatory drug), Neksium (proton pump inhibitor), and Dalacin C (oral antibiotic). Pfizer will continue to manufacture, source, and supply these medicines to Cipla for the Indian market.

This partnership is expected to leverage Cipla's extensive customer understanding, distribution reach, and network, aiming for wider reach and depth across India for these medicines. The agreement does not involve any upfront consideration paid or received, with other commercial terms agreed upon between the parties.

The collaboration marks Pfizer's first partnership with Cipla in India, combining Pfizer's established portfolio with Cipla's market reach to enhance the availability of these key brands for patients across the country.